Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 382 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malignant Melanoma of Skin Stage III Clear all
Completed Phase 3 Interventional

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

NCT00004196
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant interferon alfa, lymphangiography, Observation
Biological · Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jul 23, 2026, 5:03 AM EDT
Suspended Phase 2 Interventional

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00278122
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
sargramostim, paclitaxel
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994
View directory record Official record
Conditions
Cancer, Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo, Dacarbazine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 23, 2026, 5:03 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085397
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

NCT00002973
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, hyperthermia treatment
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003346
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
acetaminophen, acetylcysteine, carmustine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Jul 23, 2026, 5:03 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Nivolumab, BMS-986205, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 1 Interventional

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 1 Interventional

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

NCT01409174
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Temozolomide, Cisplatin, Interferon Alfa-2b, Interleukin-2
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional Results available

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

NCT02288897
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jul 23, 2026, 5:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

NCT02650986
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
Interventions
Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 1 Interventional Results available

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

NCT01519323
View directory record Official record
Conditions
Malignant Melanoma
Interventions
vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Saint Petersburgh, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 23, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional

The Multicentre Selective Lymphadenectomy Trial - 3

NCT07049276
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III
Interventions
Index lymph node resection, Therapeutic lymph node dissection
Procedure
Lead sponsor
Melanoma Institute Australia
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

NCT02306850
View directory record Official record
Conditions
Unresectable Malignant Neoplasm, Melanoma, Metastatic Melanoma, Stage IV Melanoma, Stage III Melanoma
Interventions
Pembrolizumab
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

NCT00688090
View directory record Official record
Conditions
Advanced Melanoma, Stage III and IV Melanoma
Interventions
Biological: MKC1106-MT, Biological: MKCC1106-MT
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

NCT00861406
View directory record Official record
Conditions
Melanoma
Interventions
Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 5:03 AM EDT
Not yet recruiting Phase 2 Interventional

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

NCT06708455
View directory record Official record
Conditions
Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

NCT00060333
View directory record Official record
Conditions
Recurrent Melanoma
Interventions
radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
39
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Joliet, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003647
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
Interventions
allovectin-7, allovectin-7/dacarbazine, dacarbazine
Drug
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Timeline
1998 – 2002
U.S. locations
44
States / cities
Little Rock, Arkansas • Bakersfield, California • Encinitas, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 1 Interventional Results available

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225
View directory record Official record
Conditions
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 23, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

NCT00003715
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
AVAX Technologies
Industry
Eligibility
18 Years to 120 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 23, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

NCT00591370
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide (TMZ)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 23, 2026, 5:03 AM EDT